{"id":2052,"date":"2026-09-30T15:25:24","date_gmt":"2026-09-30T20:25:24","guid":{"rendered":"https:\/\/certification.osteopathic.org\/addiction-medicine\/?page_id=2052"},"modified":"2026-09-30T15:25:24","modified_gmt":"2026-09-30T20:25:24","slug":"addiction-medicine-2027-longitudinal-assessment-references","status":"publish","type":"page","link":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/","title":{"rendered":"Addiction Medicine 2027 Longitudinal Assessment References"},"content":{"rendered":"<h2><strong>Addiction Medicine 2027 Longitudinal Assessment References<\/strong><\/h2>\n<p>Due to copyright restrictions, the Addiction Medicine Conjoint Committee cannot provide most reference materials used for longitudinal assessment. However, a list of references used for the 2027 longitudinal assessment can be found below.<\/p>\n<ul>\n<li>National Institute on Drug Abuse (Updated Jan 2024); Psychedelic and dissociative drugs as medicines<br \/>\n<a href=\"https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs-medicines\" target=\"_blank\" rel=\"noopener\">https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs-medicines<\/a><\/li>\n<li>U.S. Food &amp; Drug Administration (Updated Oct 2023); FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders<br \/>\n<a href=\"https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine\" target=\"_blank\" rel=\"noopener\">https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine<\/a><\/li>\n<li>Journal of Addiction Medicine (Sep-Oct 2023); Vol. 17, Issue 5; Evidence on buprenorphine dose limits: a review; pg. 509-516<\/li>\n<li>Experimental and Clinical Psychopharmacology (Aug 2020); Vol. 28, Issue 4; Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies; pg. 417-425<\/li>\n<li>Infectious Disease Clinics of North America (Sep 2020); Vol. 34, Issue 3; Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments; pg. 479-493<\/li>\n<li>Pediatrics (Sep 2024); Vol. 154, Issue 3; Substance use screening among youth in foster care<\/li>\n<li><a href=\"https:\/\/publications.aap.org\/pediatrics\/article-abstract\/154\/3\/e2023065057\/198911\/Substance-Use-Screening-Among-Youth-in-Foster-Care?redirectedFrom=fulltext\" target=\"_blank\" rel=\"noopener\">https:\/\/publications.aap.org\/pediatrics\/article-abstract\/154\/3\/e2023065057\/198911\/Substance-Use-Screening-Among-Youth-in-Foster-Care?redirectedFrom=fulltext<\/a><\/li>\n<li>Federal Register (Jul 2020); Vol. 85, No. 136; Confidentiality of substance use disorder patient records<\/li>\n<li>Journal of the Endocrine Society (Nov 2025); Vol. 9, Issue 11; GLP-1 therapeutics and their emerging role in alcohol and substance use disorders: an endocrinology primer<br \/>\n<a href=\"https:\/\/www.govinfo.gov\/content\/pkg\/FR-2020-07-15\/pdf\/2020-14675.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.govinfo.gov\/content\/pkg\/FR-2020-07-15\/pdf\/2020-14675.pdf<\/a><\/li>\n<li>Substance Abuse and Rehabilitation (Aug 2023); Vol. 14; Updated perspectives on the neurobiology of substance use disorders using neuroimaging; pg. 99-111<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37583934\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/37583934\/<\/a><\/li>\n<li>The Management of Substance Use Disorders Work Group (Aug 2021); VA\/DoD clinical practice guideline for the management of substance use disorders<br \/>\n<a href=\"https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VA-DoD-SUD-CPG_Final_for-508_v3.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VA-DoD-SUD-CPG_Final_for-508_v3.pdf<\/a><\/li>\n<li>The New England Journal of Medicine (Jan 2016); Vol. 374, Issue 4; Neurobiologic advances from the brain disease model of addiction; pg. 363-371<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26816013\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/26816013\/<\/a><\/li>\n<li>The Lancet Psychiatry (Aug 2016); Vol. 3, Issue 8; Neurobiology of addiction: a neurocircuitry analysis; pg. 760-773<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27475769\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27475769\/<\/a><\/li>\n<li>Frontiers in Psychiatry (Dec 2021); Vol. 12; The impact of co-occurring post-traumatic stress disorder and substance use disorders on craving: a systematic review of the literature<\/li>\n<li>StatPearls (Updated Jul 2025); Prescription of controlled substances: benefits and risks<br \/>\n<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537318\/#article-40661.s2\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537318\/#article-40661.s2<\/a><\/li>\n<li>American Heart Association (Updated Oct 2023); First responders who keep us safe need to care for themselves, too<br \/>\n<a href=\"https:\/\/www.heart.org\/en\/news\/2023\/10\/27\/first-responders-who-keep-us-safe-need-to-care-for-themselves-too\" target=\"_blank\" rel=\"noopener\">https:\/\/www.heart.org\/en\/news\/2023\/10\/27\/first-responders-who-keep-us-safe-need-to-care-for-themselves-too<\/a><\/li>\n<li>Substance Abuse and Mental Health Services Administration (Updated May 2018); Disaster Technical Assistance Center Supplemental Research Bulletin: First responders: behavioral health concerns, emergency response, and trauma<br \/>\n<a href=\"https:\/\/www.samhsa.gov\/sites\/default\/files\/dtac\/supplementalresearchbulletin-firstresponders-may2018.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.samhsa.gov\/sites\/default\/files\/dtac\/supplementalresearchbulletin-firstresponders-may2018.pdf<\/a><\/li>\n<li>Safety and Health at Work (Sep 2022); Vol. 13, Issue 4; Norms about alcohol use among US firefighters; pg. 387-393<br \/>\n<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9772477\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9772477\/<\/a><\/li>\n<li>U.S. Department of Health and Human Services (Updated Jan 2026); Fact sheet 42 CFR Part 2 final rule https:\/\/www.samhsa.gov\/about\/faqs\/confidentiality-regulations<br \/>\n<a href=\"https:\/\/www.hhs.gov\/hipaa\/for-professionals\/regulatory-initiatives\/fact-sheet-42-cfr-part-2-final-rule\/index.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.hhs.gov\/hipaa\/for-professionals\/regulatory-initiatives\/fact-sheet-42-cfr-part-2-final-rule\/index.html<\/a><\/li>\n<li>Substance Abuse and Mental Health Services Administration (Updated Oct 2023); Frequently asked questions<\/li>\n<li>Substance Abuse and Mental Health Services Administration (Updated 2019); Treatment Improvement Protocol (TIP) 35: Enhancing motivation for change in substance use disorder treatment<br \/>\n<a href=\"https:\/\/library.samhsa.gov\/sites\/default\/files\/tip-35-pep19-02-01-003.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/library.samhsa.gov\/sites\/default\/files\/tip-35-pep19-02-01-003.pdf<\/a><\/li>\n<li>The ASAM Principles of Addiction Medicine, 7th ed. (2024); Ch. 18; pg. 275<br \/>\nThe American Journal of Psychiatry Residents\u2019 Journal (Mar 2025); Vol. 20, Issue 3; Xylazine: a review of intoxication, overdose, and withdrawal symptoms<br \/>\n<a href=\"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp-rj.2025.200303\" target=\"_blank\" rel=\"noopener\">https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp-rj.2025.200303<\/a><\/li>\n<li>StatPearls (Updated Jul 2023); Xylazine toxicity<br \/>\n<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594271\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594271\/<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Addiction Medicine 2027 Longitudinal Assessment References Due to copyright restrictions, the Addiction Medicine Conjoint Committee cannot provide most reference materials used for longitudinal assessment. However, a list of references used for the 2027 longitudinal assessment can be found below. National Institute on Drug Abuse (Updated Jan 2024); Psychedelic and dissociative drugs as medicines https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs-medicines U.S. &hellip; <a href=\"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/\">Continued<\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"parent":260,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2052","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine\" \/>\n<meta property=\"og:description\" content=\"Addiction Medicine 2027 Longitudinal Assessment References Due to copyright restrictions, the Addiction Medicine Conjoint Committee cannot provide most reference materials used for longitudinal assessment. However, a list of references used for the 2027 longitudinal assessment can be found below. National Institute on Drug Abuse (Updated Jan 2024); Psychedelic and dissociative drugs as medicines https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs-medicines U.S. &hellip; Continued\" \/>\n<meta property=\"og:url\" content=\"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/\" \/>\n<meta property=\"og:site_name\" content=\"American Osteopathic Association Conjoint Examination Committee on Addiction Medicine\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/home\\\/addiction-medicine-2027-longitudinal-assessment-references\\\/\",\"url\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/home\\\/addiction-medicine-2027-longitudinal-assessment-references\\\/\",\"name\":\"Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/#website\"},\"datePublished\":\"2026-09-30T20:25:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/home\\\/addiction-medicine-2027-longitudinal-assessment-references\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/home\\\/addiction-medicine-2027-longitudinal-assessment-references\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/home\\\/addiction-medicine-2027-longitudinal-assessment-references\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\",\"item\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Addiction Medicine 2027 Longitudinal Assessment References\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/#website\",\"url\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/\",\"name\":\"American Osteopathic Association Conjoint Examination Committee on Addiction Medicine\",\"description\":\"Earn osteopathic board certification in Addiction Medicine.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/certification.osteopathic.org\\\/addiction-medicine\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/","og_locale":"en_US","og_type":"article","og_title":"Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine","og_description":"Addiction Medicine 2027 Longitudinal Assessment References Due to copyright restrictions, the Addiction Medicine Conjoint Committee cannot provide most reference materials used for longitudinal assessment. However, a list of references used for the 2027 longitudinal assessment can be found below. National Institute on Drug Abuse (Updated Jan 2024); Psychedelic and dissociative drugs as medicines https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs-medicines U.S. &hellip; Continued","og_url":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/","og_site_name":"American Osteopathic Association Conjoint Examination Committee on Addiction Medicine","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/","url":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/","name":"Addiction Medicine 2027 Longitudinal Assessment References - American Osteopathic Association Conjoint Examination Committee on Addiction Medicine","isPartOf":{"@id":"https:\/\/certification.osteopathic.org\/addiction-medicine\/#website"},"datePublished":"2026-09-30T20:25:24+00:00","breadcrumb":{"@id":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/certification.osteopathic.org\/addiction-medicine\/home\/addiction-medicine-2027-longitudinal-assessment-references\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/certification.osteopathic.org\/addiction-medicine\/"},{"@type":"ListItem","position":2,"name":"Home","item":"https:\/\/certification.osteopathic.org\/addiction-medicine\/"},{"@type":"ListItem","position":3,"name":"Addiction Medicine 2027 Longitudinal Assessment References"}]},{"@type":"WebSite","@id":"https:\/\/certification.osteopathic.org\/addiction-medicine\/#website","url":"https:\/\/certification.osteopathic.org\/addiction-medicine\/","name":"American Osteopathic Association Conjoint Examination Committee on Addiction Medicine","description":"Earn osteopathic board certification in Addiction Medicine.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/certification.osteopathic.org\/addiction-medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/pages\/2052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/comments?post=2052"}],"version-history":[{"count":1,"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/pages\/2052\/revisions"}],"predecessor-version":[{"id":2053,"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/pages\/2052\/revisions\/2053"}],"up":[{"embeddable":true,"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/pages\/260"}],"wp:attachment":[{"href":"https:\/\/certification.osteopathic.org\/addiction-medicine\/wp-json\/wp\/v2\/media?parent=2052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}